Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Form 424B3 CANTOR FITZGERALD SUSTAI
-
Jasper Therapeutics to Present at Cantor Fitzgerald’s The Future of Oncology Virtual Symposium
-
Cidara Therapeutics to Participate in Upcoming Investor Conferences
-
Form 10-K Cantor Fitzgerald Income For: Dec 31
-
Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium
-
Gradalis to Participate in the Cantor Fitzgerald Future of Oncology Symposium
-
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
-
Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium
-
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
-
Oncolytics Biotech® to Participate in a Panel Presentation at Cantor Fitzgerald's The Future of Oncology Virtual Symposium
-
Flatiron Media names Steve Kempisty as new CEO; Sheena Jacobson as SVP Sales
-
Cognition Therapeutics (CGTX) Reports FY22, Provides Business Update
-
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
-
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
-
Cidara Therapeutics (CDTX) Provides Corporate Update, Reports Q4
-
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Form 4 CANTOR FITZGERALD SUSTAI For: Mar 20 Filed by: CANTOR FITZGERALD INVESTMENT ADVISORS L.P.
-
Form 3/A CANTOR FITZGERALD SUSTAI For: Jun 30 Filed by: CANTOR FITZGERALD INVESTMENT ADVISORS L.P.
-
Form 424B3 Cantor Fitzgerald Income
-
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 Results
-
Greystone Commercial Capital Adds Senior Executives to Growing Team
-
Infinity Power Finalizes Acquisition of Lekela Power in Africa's Biggest Renewable Energy Deal
-
Form 424B3 CANTOR FITZGERALD SUSTAI
-
Analysis-Investors brace for hard landing as banking woes stoke recession fears
-
enCore Energy Commences Work to Restart Production at its 2nd South Texas Uranium Processing Plant
-
Rapt Therapeutics (RAPT) PT Lowered to $40 at Cantor Fitzgerald
-
Murano PV, S.A. DE C.V. to Become a Public Company Through Business Combination with HCM Acquisition Corp (HCMA)
-
Murano PV, S.A. DE C.V., a Mexican Development Company, to Become a Public Company Through Business Combination with HCM Acquisition Corp
-
Murano PV, S.A. DE C.V., a Mexican Development Company, to Become a Public Company Through Business Combination with HCM Acquisition Corp
-
Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion
-
Wall Street 'fear gauge' options volume jumps to 4-year high as bank stocks sell off
-
Form 486BPOS CANTOR FITZGERALD SUSTAI
-
Orchid Island Capital Announces March 2023 Monthly Dividend and February 28, 2023 RMBS Portfolio Characteristics
-
Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares in Public Offering of Common Sto
-
Cidara Therapeutics (CDTX) Prices $17.5M Common and Preferred Stock Offering
-
Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock
-
Cidara Therapeutics (CDTX) Announces Proposed Stock Offering
-
Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock
-
Form X-17A-5 CANTOR FITZGERALD & CO. For: Dec 31
-
Form 8-K Cantor Fitzgerald Income For: Feb 28
-
Cantor Fitzgerald and Silverstein Properties Announce the Closing of a $165 Million Construction Loan for 44-01 Northern Boulevard in Astoria
-
Form NPORT-P CANTOR FITZGERALD SUSTAI For: Dec 31
-
SELLAS Life Sciences (SLS) Prices 7.22M Share Offering at $2.77/sh
-
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering
-
Today's most important downgrades
-
Orchid Island Capital Announces Fourth Quarter 2022 Results
-
SELLAS Life Sciences (SLS) Announces Proposed Stock Offering
-
SELLAS Life Sciences Announces Proposed Underwritten Public Offering
-
Lucid Group (LCID) plunges on revenue miss and disappointing 2023 production guidance

